Amorphous spironolactone-hydroxypropylated cyclodextrin complexes with superior dissolution and oral bioavailability

International Journal of Pharmaceutics

Volumn 149, Issue 1, 1997, Pages 73-83

  Soliman, Osama Abd Elazeem ^a   Kimura, Kenya ^b   Hirayama, Fumitoshi ^b   Uekama, Kaneto ^b   El Sabbagh, Hassan Mohamed ^a   El Gawad, Abd El Gawad Helmy Abd ^a   Hashim, Fahima Mahmoud ^a  

^a MANSOURA UNIVERSITY   (Egypt)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Amorphous inclusion complex; Bioavailability; Crystallization; Dissolution; Hydroxypropylated cyclodextrin; Solubility; Spironolactone

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; GAMMA CYCLODEXTRIN; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ARTICLE; BIOAVAILABILITY; CIRCULAR DICHROISM; COMPLEX FORMATION; CRYSTALLIZATION; DISSOLUTION; DOG; DRUG SOLUBILITY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THERMAL ANALYSIS; X RAY DIFFRACTION;

EID: 0030956201     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(96)04862-4     Document Type: Article

References (19)

1. Agafonov, V., Legendre, B., Rodier, N., Wouessidjewe, D. and Cense, J.M., Polymorphism of spironolactone. J. Pharm. Sci., 80 (1991) 181-185.
2. Anderson, F.M. and Bundgaard, H., Inclusion complexation of spironolactone with cyclodextrins. Arch. Pharm. Chem. Sci. Ed., 11 (1983) 7-14.
3. Bettinetti, G., Melani, F., Mura, P., Monnanni, R. and Giordano, F., Carbon-13 nuclear magnetic resonance study of naproxen interaction with cyclodextrins in solution. J. Pharm. Sci., 80 (1991) 1162-1170.
4. Carr, D.S. and Hariss, B.L., Solutions maintaining constant relative humidity. Ind. Eng. Chem., 41 (1949) 2014-2015.
5. Clarke, J.M., Ramsay, L.E., Shelton, J.R., Tidd, M.J., Murray, S. and Palmer, R.F., Factors influencing comparative bioavailability of spironolactone tablets. J. Pharm. Sci., 66 (1977) 1429-1432.
6. 13C chemical shifts. J. Am. Chem. Soc., 110 (1988) 3820-3829.
7. Highet, R.J., Burke, T.R., Trager, W.F., Pohl, L.R., Menard, R.H., Taburet, A.M. and Gillette, J.R., Carbon-13 nuclear magnetic resonance studies of spironolactone and several related steroids. Steroids, 35 (1980) 119-132.
8. Higuchi, T. and Connors, K.A., Phase solubility techniques. Adv. Anal. Chem. Instrum., 4 (1965) 117-122.
9. 13C-chemical shifts and molecular dynamics of the included guests. Carbohydr. Res., 129 (1984) 9-20.
10. Levy, G., Availability of spironolactone given by mouth. Lancet, 2 (1962) 723-724.
11. McInnes, G.T., Asbury, M.J., Ramsay, L.E. and Shelton, J.R., Effect of micronization on the bioavailability and pharmacologic activity of spironolactone. J. Clin. Pharmacol., 22 (1982) 410-417.
12. Müller, B.W. and Brauns, U., Solubilization of drugs by modified β-cyclodextrins. Int. J. Pharm., 26 (1985) 77-88.
13. Pitha, J., Amorphous soluble cyclodextrins. Pharmaceutical and therapeutic uses. J. Bioact. Compat. Polym., 3 (1988) 157-163.
14. Sadee, W., Riegelman, S. and Jones, S.C., Plasma levels of spironolactone in the dog. J. Pharm. Sci., 61 (1972) 1129-1135.
15. Seo, H., Tsuruoka, M., Hashimoto, T., Fujinaga, T., Otagiri, M, and Uekama, K., Enhancement of oral bioavailability of spironolactone by β- and γ-cyclodextrin complexations. Chem. Pharm. Bull., 31 (1983) 286-291.
16. Uekama, K., Horiuchi, Y., Kikuchi, M., Hirayama, F., Ijitsu, T. and Ueno, M., Enhanced dissolution and oral bioavailability of α-tocopheryl esters by dimethyl-β-cyclodextrin complexation, J. Incl. Phenom., 6 (1988) 167-174.
17. Uekama, K., Ikegami, K., Wang, Z., Horiuchi, Y. and Hirayama, F., Inhibitory effect of 2-hydroxypropyl-β-cyclodextrin on crystal growth of nifedipine during storage: superior dissolution and oral bioavailability compared with polyvinylpyrrolidone K-30. J. Pharm. Pharmacol., 44 (1992) 73-78.
18. Weuner, I.M. and Mudge, G. (1985) In Gilman, A.G., Goodman, L.S., Roll, T.W. and Murd, F. (Eds.). Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 7th Edn, Chapter 36. Macmillan, New York, p. 900.
19. Yusuff, N. and York, P., Spironolactone-cyclodextrin complexes: phase solubility and ultrafiltration studies. Int. J. Pharm., 73 (1991) 9-15.